Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03958071 · ClinicalTrials.gov registry record
A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients Grouped by the Type of Medication They Are Taking
A clinical trial of Idiopathic Pulmonary Fibrosis, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 13,264
- Enrollment target
- 1
- Study location
NCT03958071 is a study of Idiopathic Pulmonary Fibrosis that has completed, run by Boehringer Ingelheim. The registered enrollment target is 13,264 participants, above the 491-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (2601% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03958071, a study of Idiopathic Pulmonary Fibrosis, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 13,264 participants
- Enrollment target
- 1
- Study location
Study Summary
To understand differences in characteristics of Idiopathic Pulmonary Fibrosis (IPF) patients who are prescribed nintedanib compared to those who are prescribed pirfenidone.
Conditions Studied
Interventions
- DRUG Pirfenidone
- DRUG Nintedanib
- OTHER Untreated Cohort
Study Locations (1)
Pennsylvania
- Plymouth Meeting - Plymouth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13,264 participants |
| Start Date | 2019-02-01 |
| Est. Completion | 2019-05-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03958071
The ClinicalTrials.gov registry entry for NCT03958071 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 13,264 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 491-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (2601% higher). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 3 interventions - of which Pirfenidone is the first listed.
NCT03958071 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03958071 about?
NCT03958071 is a clinical study titled "A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients Grouped by the Type of Medication They Are Taking". To understand differences in characteristics of Idiopathic Pulmonary Fibrosis (IPF) patients who are prescribed nintedanib compared to those who are prescribed pirfenidone.
What is the current status of trial NCT03958071?
This trial is currently completed. The enrollment target is 13,264 participants. The study started on 2019-02-01. Estimated completion is 2019-05-31.
What conditions does trial NCT03958071 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis.
What interventions are being tested in trial NCT03958071?
The interventions under investigation include: Pirfenidone (DRUG), Nintedanib (DRUG), Untreated Cohort (OTHER).
Who is sponsoring clinical trial NCT03958071?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03958071 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis
RECRUITING · Early Phase 1
-
Pulmonary Fibrosis Foundation Community Registry
RECRUITING
-
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
RECRUITING · Phase 2
-
Interstitial Lung Disease Research Unit Biobank
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.